Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07462702 | Topical Minocycline for CARP | EARLY_PHASE1 | NOT YET_RECRUITING | 35 | — | — | Jun 1, 2026 | Dec 1, 2027 | Mar 10, 2026 | - | — |
Comparison between the efficacy of topical minocycline foam and the control emollient. This will be completed by a dermatologist or dermatology resident that will be blinded to which side was treated with which intervention. Assessment will be completed through a visual analog used by the assessor where REDCap will assign a numeric value based on the position of the marking. The blinded photo reviewer will be informed whether the photo is a baseline or follow-up photo, but will be blinded to which side of the body was treatment or control. The photos will be marked to indicate the side of the body, and the photo reviewer will be asked to compare the left baseline side to the left follow-up side, and similarly the right baseline to the right follow-up, using a visual sliding analogue scale, where REDCap will assign a numeric value based on the position of the marking indicator. Average response to treatment among all patients will be determined.
| Arm | Type | Description |
|---|---|---|
| Experimental Half of the Body | EXPERIMENTAL | Participants will apply the investigational topical medication to one half of the body that they choose |
| Control Half of the Body | PLACEBO_COMPARATOR | Participants apply the control topical emollient without active ingredient to the contralateral half of the body |
| Name | Type | Description |
|---|---|---|
| Topical Minocycline Foam FXFM244 | DRUG | Topical minocycline foam that will be applied to half of the subject's body that will be chosen by the subject. |
| Control | OTHER | Control topical emollient that will be applied to the contralateral half of the body. |
Inclusion Criteria: * Age ≥ 9 years * Clinical diagnosis of CARP Exclusion Criteria: * Current or recent (within 6 months) use of oral minocycline * Pregnancy or breastfeeding * History of intracranial hypertension, autoimmune disorder, liver/kidney disease * Immunocompromised status * Hypersensi...